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KAJIAN BERPANDUKAN AKTIVITI ANTI-DIABETIK EKSTRAK DAUN 
SYZYGIUM POLYANTHUM (WIGHT) DAN ELUSIDASI MEKANISME 
KERJANYA 
 
ABSTRAK 
 
Kajian berpandukan aktiviti anti-diabetik telah dilakukan terhadap daun 
Syzygium polyanthum  suatu ubatan tradisional yang popular di utara Sumatera, 
Indonesia. Aktiviti anti-diabetik telah dinilai dengan menentukan samaada daun 
tersebut dapat menurunkan paras glukosa darah (BGL) tikus normal (ujian 
hipoglisemik), merencat peningkatan BGL tikus yang diberikan beban glukosa 
secara intraperitoneal (ujian toleransi glukosa) dan menurunkan BGL tikus diabetik 
aruhan streptozotosin. Serbuk kering daun S. polyanthum telah diekstrak secara 
bersiri dengan eter petroleum (PEE), kloroform (CE), metanol (ME) dan air (WE). 
Dalam tikus diabetik, pemberian dengan dos tunggal ekstrak-ekstrak menunjukan 
hanya ME menurunkan BGL, sedangkan pemberian dos berulang selama 6 hari, 
kedua-dua PEE dan ME menurunkan BGL secara signifikan. Oleh itu, ME 
seterusnya difraksikan kepada fraksi kloroform (CF), etil asetat (EAF), n-butanol (n-
BF) dan air (WF). Didapati pemberian dos berulang CF dan WF dapat menurunkan 
BGL tikus diabetik. CF kemudiannya digoncang dengan n-heksana menjadi fraksi 
tidak larut (SF-1) dan fraksi larut (SF-2). Hanya SF-1 menurunkan  BGL tikus 
diabetik. GC-MS dapat mengenal pasti kehadiran skualena (SQ) di dalam ME, CF 
dan SF-1. Pemberian berulang SQ menurunkan BGL secara bergantungan dos pada 
tikus diabetik mencadangkan SQ adalah salah satu sebatian dalam daun S. 
polyanthum yang menyumbang kepada kesan anti-diabetiknya. Pemberian dos 
 xxi 
 
berulang ME, CF, WF, SF-1 dan SQ selama 12 hari menunjukkan bahwa ME 
sebagai ekstrak paling aktif dalam menurunkan paras glukosa tikus diabetik. 
Penilaian imunohistokimia menunjukkan bahawa strepozotosin 55 mg/kg merosak 
struktur pulau Langerhans dan fungsi sel β tikus dan tidak ada rawatan yang dapat 
mengembalikan kesan kerosakan ini. Kedua-dua cerakin perencatan  enzim α-
glukosidase dan α-amilase menunjukan bahawa SF-1 dan SQ dapat merencat enzim-
enzim ini sedangkan CF dan ME merencat aktiviti α-glukosidase. Sediaan kantung 
jejunum yang diterbalikkan menunjukkan ME, CF, WF, SF-1 dan SQ merencat 
penyerapan glukosa. Ujian toleransi glukosa oral menunjukkan ME dan CF 
mengurangkan luas dibawah kelok (AUC) yang berhubungan dengan perencatan 
aktiviti α-glucosidase dan α-amilase in vivo. Tambahan pula, pengambilan glukosa 
oleh kedua-dua otot abdomen dan soleus ditingkatkan oleh ME, CF, WF, SF-1 dan 
SQ. Penyelidikan ini memberikan data saintifik ekstrak metanol daun S. polyanthum 
sebagai ekstrak paling aktif. Mekanisme tindakan anti-diabetik daun S. polyanthum 
adalah melalui perencatan enzim α-glukosidase dan α-amilase, perencatan 
penyerapan glukosa di usus serta meningkatkan ambilan glukosa di otot-otot.  
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ANTI-DIABETIC ACTIVITY-GUIDED STUDIES OF SYZYGIUM 
POLYANTHUM (WIGHT) LEAF EXTRACTS AND ELUCIDATION OF 
THEIR MECHANISMS OF ACTION 
 
ABSTRACT 
 
Anti-diabetic activity guided studies were performed on the leaves of 
Syzygium polyanthum, a popular traditional medicinal herb in north Sumatera, 
Indonesia. The anti-diabetic activity was evaluated by determining whether the 
extracts lowered the blood glucose levels (BGL) of normal rats (hypoglycaemic test), 
inhibited the rise of BGL of intraperitoneally glucose- loaded rats (glucose tolerance 
test) and lowered BGL of streptozotocin-induced diabetic rats. Dried powdered S. 
polyanthum leaves were extracted serially with petroleum ether (PEE), chloroform 
(CE), methanol (ME) and water (WE). In diabetic rats, single-dose administration of 
the extracts showed that only ME reduced BGL. However, upon repeated-dose 
administration for 6 days both PEE and ME reduced BGL significantly. Therefore, 
liquid-liquid partition was used to fractionate ME into the following fractions: 
chloroform (CF), ethyl acetate (EAF), n-butanol (n-BF) and water (WF). Repeated 
administration of CF and WF decreased BGL of diabetic rats. CF was shaken with n-
hexane to yield an undissolved fraction (SF-1) and a dissolved fraction (SF-2). Only 
SF-1 lowered BGL of diabetic rats. GC-MS identified the presence of squalene (SQ) 
in ME, CF and SF-1.  Repeated administration of SQ reduced BGL of diabetic rats. 
This suggests that SQ is one of the compounds in S. polyanthum leaf that contribute 
to its anti-diabetic activity. Repeated-dose for 12 days of ME, CF, WF, SF-1 and SQ 
proved that ME was the most active blood glucose lowering agent. 
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Immunohistochemical staining revealed that streptozotocin 55 mg/kg  obliterated the 
structure of the islet of Langerhans and the function of β-cells of rats and none of 
treatments could reverse the effect. In vitro -glucosidase and -amylase inhibition 
assays showed that SF-1 and SQ were able to inhibit both of these enzymes, whereas 
CF and ME inhibited -glucosidase activity only. In averted jejunal sac studies, ME, 
CF, WF, SF-1 and SQ inhibited glucose absorption. Oral glucose tolerance tests 
showed that ME and CF reduced the area under the curve (AUC), which reflected -
glucosidase and -amylase inhibition activities in vivo.  Furthermore, glucose uptake 
into both abdominal and soleus muscles was increased by ME, CF, WF, SF-1 and 
SQ. The present work provides scientific data that indicates that the methanolic 
extract of S. polyanthum (Wight) leaf is the most active extract. The anti-diabetic 
mechanisms of action of S. polyanthum involved enzyme inhibition (-glucosidase 
and -amylase), intestinal glucose absorption inhibition and increased glucose 
uptake by the muscles. 
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CHAPTER ONE 
INTRODUCTION 
1.1. Diabetes mellitus 
1.1.1. Definition and historical aspect 
Diabetes mellitus is a common group of metabolic disorders (American Diabetes 
Association[ADA], 2010)  that is characterized by hyperglycaemia resulting from 
relative insulin deficiency or insulin resistance or both (Innes, 2009; Lenzen, 2008). 
Hyperglycaemia, a term denoting a high blood glucose level, has been defined by the 
World Health Organisation as a blood glucose level that is greater than 7.0 mmol/L 
(126 mg/dL) when fasting and greater than 11.0 mmol/L (200 mg/dL) 2 hours after a 
meal (Diabetes.co.uk, 2015). 
 
As early as 200 years before the Christ, Greek physician Aretaeus had observed 
patients showing symptoms of excessive thirst and urination. He called this condition 
“diabetes,” which means “to siphon”, or “ to pass through” in Greek. Afterwards, 
physicians added “mellitus” (Latin for “honeyed, sweet”) to the disease name after 
observing that the diabetic patients produced urine that contained glucose.  The 
terminology of diabetes mellitus also distinguishes this disorder from diabetes 
insipidus (Shu & Myers, 2004). Chronic hyperglycaemia, the main symptom of 
diabetes, is associated with long-term damage, dysfunction, and failure of different 
organs, especially the eyes, kidneys, nerves, heart, and blood vessels (American 
Diabetes Association[ADA], 2012). 
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 1.1.2. Epidemiology 
Diabetes mellitus exists world-wide where 171 million people were diagnosed with 
diabetes in 2000, and this is expected to double by 2030. A substantial rise will  most 
likely happen in the developing countries. Asia contributes more than 60% of the 
world's diabetic population, and has the greatest burden of  type 2 diabetes mellitus 
(T2DM) (Innes, 2009; Mu et al., 2012).  Furthermore, four of the top-ten countries 
with the largest diabetic populations are in Asia. They are Indonesia, Pakistan, 
Bangladesh, and the Philippines (Ramachandran, Ma, & Snehalatha, 2010).    
 
1.1.3. Anatomy of the pancreas 
The pancreas is a glandular organ that contains both exocrine and endocrine tissue 
(Compton et al., 2012). The exocrine portion-which constitutes 99% of the 
pancreatic mass-secretes bicarbonate and digestive enzymes into the gastrointestinal 
(GI) tract. Scattered within the exocrine tissues are nearly one million small islets of 
endocrine tissues that secrete hormones directly into the blood. These tiny endocrine 
glands are known as the islets of Langerhans (IL). They are clusters of cells, with 
each  islet containing 3,000 to 4,000 cells (Diabetes Research Institute Foundation 
[DRIF], 2014). They include diverse cell types, that secrete different hormones, such 
as the glucagon-secreting -cells, the insulin-secreting -cells, the somatostatin- and 
gastrin-secreting -cells, and the pancreatic polypeptide-secreting PP or F cells. A 
Langerhans islet is composed in 60-80% of -cells and forms its central core with -,  
- and  F-cells (Brunton & Parker, 2006; Shu & Myers, 2004).   
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1.1.4. Physiological regulation of glucose homeostasis and insulin action 
Blood glucose is maintained within a narrow range by homeostatic mechanisms 
(Innes, 2009).  The human body strictly maintains normal blood glucose levels 
(normoglycaemia) in the range of 4-6 mmol/L when fasting and 7.8 mmol/L 2 hrs 
after eating (Chew & Leslie, 2006; Diabetes.co.uk, 2015). To maintain homeostasis, 
the rate of glucose utilization  (Wang et al., 1999)  by the peripheral tissues should be 
matched with the rate of glucose production  (Chew & Leslie, 2006).  In the 
gastrointestinal tract, complex dietary carbohydrates are broken down to glucose by 
glucosidase enzymes. Glucose is absorbed by the gastrointestinal epithelial cells and 
transported into the blood stream.  Glucose in the blood is distributed to all 
metabolically active tissues in the body.  In pancreatic -cells, glucose metabolism 
raises the level of cytosolic ATP, which stimulates insulin secretion.  Then, insulin 
acts on the insulin receptors on the plasma membrane of target tissues, such as the 
muscles, adipose tissues, and liver to increase glucose uptake and glucose storage as 
glycogen or triglyceride (TG). Glucose is also taken up by other cells and tissues to 
fuel metabolism.  In muscle and liver cells, insulin promotes glucose storage as 
glycogen; whereas in adipose cells, insulin and the peroxisome proliferator-activated 
receptors  (PPAR) promote glucose conversion to TG. If necessary, glucagon 
would promote both the conversion of glycogen back to glucose (glycogenolysis), 
and gluconeogenesis. Glucose would then be carried out of the liver cells and into the 
bloodstream (Figure 1.1.) (Shu & Myers, 2004). Therefore, insulin is the key 
hormone which regulates both the storage and the controlled release of the chemical 
energy obtained from food (Chew & Leslie, 2006). When intestinal glucose 
absorption declines between meals, hepatic glucose output is increased in response to 
lower insulin levels and increased levels of the counter-regulatory hormones, 
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glucagon and adrenaline (epinephrine). The liver produces glucose by 
gluconeogenesis and glycogen breakdown. After meals, blood insulin levels rise in 
response to a rise in blood glucose levels (Innes, 2009).  
 
Glucagon-like peptide-1(7-36)amide (GLP-1), an incretin (gut hormone), also acts as 
a key determinant of blood glucose homeostasis by enhancing pancreatic insulin 
secretion after meal ingestion in a glucose-dependent manner, which results in 
delayed postprandial hyperglycaemia (Figure 1.1). GLP-1 is secreted from the L-
cells of the gastrointestinal mucosa in response to meals, to activate enteric and 
autonomic reflexes, while also circulating as an incretin hormone to control the 
endocrine pancreatic functions. Its action is terminated via enzymatic degradation by 
dipeptidyl-peptidase-IV (DPP-IV). The glucagon-like peptide-1 receptor (GLP-1R) 
is a G protein-coupled receptor that is activated directly or indirectly by blood 
glucose-lowering agents currently in use for the treatment of type 2 diabetes mellitus 
(T2DM), including GLP-1R agonists and DPP-IV inhibitors (Drucker, 2006;   Camp-
bell & Drucker, 2013; Nadkarni, Chepurny & Holz 2014). 
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         Figure 1.1. Physiological and pharmacological regulation of glucose homeostasis (Adapted from Shu and Myers, 2004 with 
         modification).  
        (GIT: Gastrointestinal tract, ATP: Adenosine triphosphates, PPAR: Peroxisome proliferator-activated receptor ; 
        GLP-1R: Glucagon-like peptide-1 receptor; DPP-IV: dipeptidyl-peptidase-IV; : Glucose; : Insulin) 
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1.1.5.Pathophysiology 
Several pathogenic processes are involved in the development of diabetes (American 
Diabetes Association[ADA], 2012). Basically, hyperglycaemia occurs as a result of 
an absolute lack of insulin (Type I diabetes mellitus, also called insulin-dependent 
diabetes mellitus (IDDM) or juvenile-onset diabetes) or relative insufficiency of 
insulin production due to  insulin resistance (Type II diabetes mellitus, also called 
non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes), or both 
(Innes, 2009; Lenzen, 2008; Shu & Myers, 2004). These conditions cause 
incapability to store glucose in the cells.  
 
In IDDM,  a cellular-mediated autoimmune response destroys the insulin producing  
-cells in the pancreas.  On the other hand, NIDDM, ranges in etiology from 
predominant insulin resistance, with relative insulin deficiency, to a predominant  
insulin secretory defect, with insulin resistance. Moreover, most of NIDDM patients 
are obese, and obesity itself causes insulin resistance (American Diabetes 
Association[ADA], 2012; Shu & Myers, 2004). 
 
1.1.6. Clinical manifestation and complications 
Patients with diabetes mellitus present with symptoms or clinical problems resulting 
from high blood glucose levels. The classical symptoms are (Chew & Leslie, 2006) 
polyuria, caused by the osmotic diuresis that occurs when blood glucose levels 
exceed the renal threshold; polyphagia, which means excessive hunger; polydipsia 
(thirst), caused by the loss of fluids and electrolytes; and weight loss, caused by fluid 
depletion and the accelerated breakdown of fat and muscles which is secondary to 
insulin deficiency.  
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Diabetes complications are categorized into microvascular and macrovascular. The 
microvascular complications result from damages to small blood vessels and 
comprise condition such as retinopathy (damage to the eyes), nephropathy (damage 
to the kidnesy leading to renal failure), and neuropathy (damage to the nerves leading 
to impotence and diabetic foot disorders). The macrovascular complications include 
cardiovascular events such as heart attack, stroke and insufficient blood flow to the 
legs (World Health Organization WHO, 2015). 
 
1.1.7. Classification 
The clinical classification of diabetes includes : 
1.  Type 1 diabetes: It results from -cell destruction and usually leads to absolute 
insulin deficiency. This type is underlined by a slow progessive T cell-mediated 
autoimmune disease (Concannon, Rich, & Nepom, 2009) that leads to the 
destruction of the insulin-secreting -cells. Classical symptoms of diabetes occur  
when 70-90% of the -cells have been destroyed (Sacks, 2011). 
2. Type 2 diabetes: It results from a progessive insulin secretory defect or insulin 
resistance. In this type, patients retain some capacity to secrete insulin but there 
is a combination of resistance to the actions of insulin and impaired pancreatic 
-cell function, which lead to „relative‟ insulin deficiency (Innes, 2009). The 
progession of type 2 diabetes is thought to begin with a state of  insulin 
resistance (Shulman, 2000) whereby tissues that are normally insulin-responsive 
become relatively refractory to insulin action, and require higher levels of 
insulin to give appropriate responses (Shu & Myers, 2004) 
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3. Other specific types of diabetes which are due to other causes such as genetic 
defects in -cell function, or insulin action, diseases of the exocrine pancreas 
(like cystic fibrosis), and drugs or chemicals (as seen in the treatment of 
HIV/AIDS and after organ transplantation).  
4. Gestational diabetes mellitus (GDM): It is diagnosed during pregnancy and it is 
not a distinct form of diabetes. This type is defined as any abnormality in 
glucose levels noticed for the first time during pregnancy. GDM may be caused 
by the placenta and placental hormones, which can create insulin resistance that 
is pronounced in the last trimester (Nolte & Karam, 2004). 
  
1.1.8.Diagnosis 
Blood glucose levels are assessed in two ways, namely acute measurement, whereby 
blood glucose is measured using a glucose monitor at a single point in time, and 
chronic measurement, which involves the measurement of glycohemoglobin 
(HbA1c) (Shu & Myers, 2004). HbA1c forms when haemoglobin joins with glucose 
in the blood. Refered as glycated haemoglobin (A1c), this test evaluates the average 
plasma glucose concentration (Diabetes.co.uk, 2015).    
 
Table 1.1. Criteria for the diagnosis of diabetes (American Diabetes 
Association[ADA], 2013). 
 
HbA1c  6.5%. The test should be performed in a laboratory using the method of 
the National Glycohemoglobin Standardization Progam (NGSP) as certified and 
standardized to the Diabetes Control and Complications Trial (DCCT) assay.* 
OR 
Fasting plasma glucose (FPG)   126 mg/dL (7.0 mmol/L). Fasting is defined as no 
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caloric intake for at least 8 hour.* 
OR 
2-hour plasma glucose  200mg/dL (11.1mmol/L) during an oral glucose tolerance 
test (OGTT). The test should be performed as described by WHO, using a glucose 
load containing the equivalent of 75 g of anhydrous glucose dissolved in water.* 
OR 
In a patient with classical symptoms of hyperglycaemia or hyperglycaemic crisis, a 
random plasma glucose  200 mg/dL (11.1 mmol/L). 
*In the absence of unequivocal hyperglycaemia, the results should be confirmed by 
repeated testing. 
 
1.1.9. Treatment 
The aim of the treatment of diabetes is to achieve near normal metabolism. The 
recommended target is HbA1c   7% (Innes, 2009) to decrease the risk of long-term 
complications (Shu & Myers, 2004). „Anti-diabetic‟ denotes an agent that prevent or 
alleviates diabetes (“Antidiabetic”, n.d.). The available currently used anti-diabetic 
agents are: 
1. Exogenous insulin (Insulin replacement therapy). 
Insulin is the mainstay for treatment in patients diagnosed with type 1 DM, and most 
of type 2 DM patients (Brunton & Parker, 2006). Insulin preparations are classified 
according to their onset of action, duration of action, and species of origin (i.e., 
human, pig, or cow).  
2. Amylinomimetics. 
Pramlintide is a synthetic amylin analog that is indicated as an adjunct to mealtime 
insulin therapy in patients with type 1 and type 2 diabetes. Acting as an 
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amylinomimetic, pramlintide delays gastric emptying time, decreases postprandial 
glucagon secretion, and improves satiety (Harvey, 2012). 
3.Inhibitors of intestinal glucose absorption: -Glucosidase inhibitors. 
-glucosidase inhibitors reduce intestinal absorption of starch, dextrin, and 
disaccharides by inhibiting the action of -glucosidase in the intestinal brush border.  
Consequently, the postprandial rise in plasma glucose levels is delayed in both 
normal and diabetic subjects (Brunton & Parker, 2006). 
4. Insulin secretagogues: sulfonylureas and meglitinides. 
The major action of sulfonylureas is to increase insulin release from the pancreas. 
Two additional mechanisms of action for sulfonylureas have been proposed, which 
involve reduction of serum glucagon levels and closure of the potassium channels in 
extrapancreatic tissues. Meglitinides make a relatively new class of insulin 
secretagogues. These drugs modulate -cell insulin release by regulating potassium 
efflux through the potassium channels. Unlike sulfonylureas, meglitinides  have no 
direct effect on insulin exocytosis (Nolte & Karam, 2004).  
5. Insulin sensitizers: thiazolidinediones and biguanides 
Thiazolidinediones (TZDs) do not affect insulin secretion, but rather enhance the 
action of insulin at the target tissues. TZDs are agonists for the nuclear hormone 
receptor, namely the peroxisome proliferator activated receptor-ϓ (PPAR ϓ). Like 
TZDs, biguanides act by increasing insulin sensitivity. The molecular target of  
biguanides seems to be the AMP-dependent Protein Kinase (AMPPK). Biguanides 
activate AMPPK to block the breakdown of fatty acids and inhibit hepatic 
gluconeogenesis and glycogenolysis (Shu & Myers, 2004). 
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6. Dipeptidyl peptidase-IV inhibitors (DPP-IV inhibitors) 
These drugs inhibit the enzyme DPP-IV, which is responsible for the inactivation of 
the incretin hormones such as glucagon-like peptide-1 (GLP-1). Prolonging the 
activity of the incretin hormones causes increased insulin release in response to 
meals and a reduction of inappropriate secretion of glucagon. A DPP-IV inhibitor 
may be used as monotherapy or in combination with a sulfonylurea, metformin, 
glitazone, or insulin (Harvey, 2012). 
7. Incretin mimetics. 
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is secreted by the L 
cells of the intestine upon meal ingestion.  However, this hormone has a very short 
half-life as it is degraded by the ubiquitous enzyme dipeptidyl-peptidase IV (DPP-
IV) (Tushuizen et al., 2006). Therefore, incretin mimetics, which are analogs of 
GLP-1,  exert their activity by acting as GLP-1 receptor agonists.  These agents 
improve  glucose-dependent insulin secretion, slow gastric emptying time, decrease 
food intake, decrease postprandial glucagon secretion, and promote -cell 
proliferation.  Consequently, the weight gain, the postprandial hyperglycaemia and 
HbA1c levels are reduced (Drucker & Nauck, 2006; Harvey, 2012; Tushuizen et al., 
2006). 
 
1.2. Medicinal plants of the Syzygium genus 
Traditional medicines that are derived from medicinal plants are used by about 60% 
of the world‟s population (Modak et al., 2007). From the ancient times, such 
materials have been used for the treatment of diabetes mellitus, and are still being 
used extensively in present traditional of folk medicines (Evans, 2009). So far, a 
number of the medicinal plants that are used to treat diabetes have been proven to 
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possess  anti-diabetic activity in vitro, in vivo and in clinical studies (Elfahmi, 2006). 
Some of these plants belong to Syzygium genus. 
 
Herbs of the Syzygium genus reported to be anti-diabetic: 
1. Syzygium cumini 
Syzygium cumini (SC) (Myrtaceae) is widely used in traditional medicine to treat 
diabetes in India.  Kumar et al. (2008) isolated a compound, mycaminose, from SC 
seed extract. The isolated mycaminose (50 mg/kg) together with the ethyl acetate 
(EA) and the methanol (ME) extracts of the plant were used to evaluate the anti-
diabetic activity in STZ-induced diabetic rats. The results of this study indicated that 
mycaminose, and the EA and ME extracts exerted anti-diabetic effects in STZ-
induced diabetic rats.   
2. Syzygium alternifolium (Wt.) Walp. 
The aqueous, ethanolic and hexane fractions of S. alternifolium seeds have been 
investigated in both normal and alloxan diabetic rats (Kameswara & Appa, 2001).   
The aqueous extract of S. alternifolium at a dose of 0.75 g/kg showed a blood 
glucose lowering effect in both normal and alloxan diabetic rats. The ethanol and 
hexane fractions also showed both hypoglycaemic and anti-hyperglycaemic activites, 
but the effects were significantly less than those of the aqueous extract.  
3. Syzygium malaccense 
Arumugam et al. (2014) reported the -glucosidase and -amylase inhibitory 
activities of myricetin, a compund identified in S. malaccense leaf extract. 
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4. Syzygium aromaticum (L.) Merr. & Perry (clove) 
A S. aromaticum clove bud diet has been reported to attenuate hyperglycaemia, 
hyperlipidemia, hepatotoxicity and oxidative stress in a type 2 diabetic rat model, in 
which diabetes is induced by a combination of a high-fat diet and a low dose of 
streptozotocin (35 mg/kg) for 30 days (Adefegha, 2014). 
 
1.3. Syzygium polyanthum (Wight.) 
1.3.1. Synonyms and common names 
Syzygium polyanthum (Wight) is synonym to Eugenia balsamea Ridley, Eugenia 
nitida Duthie and Eugenia polyantha Wight (Seidemann, 2005). This plant is also 
known with several common local names, such as daun salam, ubar serai, 
meselengan  (in Sumatera); samak, kelat samak, serah  (in Malaysia)  and manting 
(in Jawa)(Agoes, 2010). Other names for this plants include Indonesisch laurierblad 
(in the Dutch language); Indian bay leaf, and Indonesian bay leaf, Indonesian laurel 
(in English); Pring sratoab (in the Khmer dialect);  Daeng klua, Dok maeo, Mak (in 
Thai) and San thuyen (in Vietnamese) (Michel, 2011). 
 
1.3.2. Taxonomy  (Wasito, 2011) 
Kingdom Plantae 
Division Magnoliophyta 
Class Magnoliopsida 
Order Myrtales 
Family Myrtaceae 
Genus Syzygium 
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Species polyanthum 
 
1.3.3. Structural features  
S. polyanthum trees are medium-sized, evergeen trees with dense crowns. They can 
grow up to 30 meters. The bark is grayish brown, and appears cleaved /cracked or 
scaly. The leaves are single and exist in an opposite formation with  petioles that are  
up to 12 mm long.  The flowers are small and fragrant with like bowl-petals. The 
fruits are dark red to purplish-black when ripe (Agoes, 2010).   
 
1.3.4.Geography  
S. polyanthum grows wild in forests and mountains or is usually planted in the yard 
and around the house. The plant can grow in low-lying areas to a height of 1,400 m 
above sea level. It is commonly grown for the leaves to be used as a complementary 
herbal remedy, and for the tree bark to be used as a dye (Wasito, 2011). It grows in 
thickets, bamboo forests and teak plantations. It grows in high-altitude areas up to 
1,000 m of altitude in Java, 1,200 m of altitude in Sabah, Malaysia and 1,300 m of 
altitude in Thailand. It is widely distributed in Burma (Myanmar), Indo-China, 
Thailand, Malaysia, and Indonesia (Java, Sumatera, Kalimantan). S. polyanthum may 
produce flowers upon being as young as 3 years old. Flowering and fruit bearing are 
more or less year-round. The flowers last for 4-7 days and are usually pollinated by 
beetles and butterflies (Agoes, 2010). 
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Plate 1.1.  Syzygium polyanthum (Wight.) (“Useful Tropical Plants”, n.d.) 
(a-b. S. polyanthum tree; c.Trunk; d.Leaves; e. Flowers and developing fruits; 
f.Ripening fruits) 
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1.3.5. Phytochemical constituents 
Agoes (2010) mentioned that the dry leaves of S. polyanthum consisted in about 
0.17% of essential oils, such as eugenol and methyl chavicol. Examination of the 
crude extract of S. polyanthum leaves showed that it consisted of tannins (ethanol 
insoluble) at 90.95% and polar compounds at 8.8% (Anggorowati, Sukrasno, & 
Adnyana, 2004). The volatile components in fresh S. polyanthum leaves mostly 
consists of terpenoids (Arintawati, 2000). A phytochemical screening study 
conducted by Kusuma et al. (2011) reported that the ethanolic extract of S. 
polyanthum leaves contained alkaloids, carbohydrate, tannins, steroids, triterpenoids 
and flavonoids, with no trace of saponin. 
 
1.3.6. Traditional uses 
S. polyanthum leaves are traditionally used as a remedy for gout, stroke, high blood 
cholesterol levels, poor blood circulation, gastritis, diarrhea, urticaria, hypertension, 
and diabetes mellitus (Agoes, 2010).  Widyawati et al. (2012) reported that most 
diabetic patient in Puskesmas Sering, Medan, Indonesia, used S. polyanthum as a 
traditional medicine for their disease. 
 
1.3.7. Pharmacological activity 
Several anti-hyperglycaemic test have been conducted on S. polyanthum leaf using 
the alloxan-induced diabetic mice model. A drug that is described as „anti-
hyperglycaemic‟ is an agent that counteracts high levels of blood glucose or  
hyperglycaemia. It is a condition that describes blood glucose levels greater than 7.0 
mmol/L when fasting, or greater than 11.0 mmol/L 2 hours after a meal 
(“Antihyperglycemic”, n.d.).   
17 
 
A study conducted by Anggadiredja (1998) showed that the ethanol-insoluble 
aqueous fraction (0.7 g/kg) of the extract of S. polyanthum leaves reduced the blood 
glucose concentration in alloxan-induced diabetic mice, but the effect was less potent 
than insulin. Studiawan and Santosa (2005) reported that the ethanol extract of S. 
polyanthum leaves significantly decreased the blood glucose levels of alloxan-
induced diabetic mice at the doses of 2.62 mg/20 g and 5.24 mg/20 g. Furthermore, 
30% and 70% ethanolic extracts of S.polyanthum were shown to significantly inhibit 
the rise of blood glucose levels after glucose loading in rabbit (Wahyono and 
Susanti, 2008). 
 
Riansari & Suhardjono (2008) showed that the oral administration of three doses of 
S. polyanthum ethanol extracts (0.18 g, 0.36 g and 0.72 g) daily for 15 days resulted 
in significant reduction of the total serum cholesterol levels in hyperlipidemic Wistar 
rats. A dose of 0.72 g daily for 15 days showed the greatest reduction in the observed 
effect.    
 
The antioxidant and cytotoxic activities of methanolic extracts from S. polyanthum 
have also been investigated. The results revealed that the methanolic extracts of S. 
polyanthum possessed promising antiradical properties (Perumal et al., 2012).  The 
findings were similar to those of a study conducted by Lee & Ismail (2012), which 
showed that the methanolic extract of S. polyanthum leaves demonstrated a mild anti-
oxidant activity.  
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Despite the extensive use of S.polyanthum leaf by Indonesian people as traditional 
medicine, there has only been limited scientific data relevant to explore the 
mechanisms and bioactive compounds of this plan in relation to their medicinal uses 
as anti-diabetics. None of the previous works was based on a bioactivity-guided anti-
diabetic study. The bioactivity-guided approach, when employed in initial screening 
of herbal extracts for a biological activity, paves the way for easy identification of 
the active principle(s). Therefore, the present study investigated the anti-diabetic 
activity of S.polyanthum leaf and its mechanisms of action using a bioactivity-guided  
approcah. 
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Extraction of plant material (Four extracts obtained) 
Male Sprague-Dawley (SD) Rats 
                                                              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Flowchart of the research activities. 
 
 
 
Anti-hyperglycaemic test with repeated 
dose of the 4 extracts 
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Glucose 
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(IPGTT) with 
the 4 extracts.  
Anti-hyperglycaemic test with single 
dose of the 4 extracts 
Anti-hyperglycaemic test with repeated 
dose of  the 4 fractions  
 
fractions.  
Anti-hyperglycaemic test with repeated 
dose of the  active compound.  
Anti-hyperglycaemic test with repeated dose 
of  the 2 sub fractions 
Antihyperglycaemic test of different 
doses of methanol extract  
Non-Diabetic Rats 
(NDR) 
STZ-induced Diabetic Rats (SDR) 
Active extract, fraction, subfraction, active compound 
Insulin 
assay 
Measurement of 
glucose uptake by 
isolated rat 
abdominal and soleus 
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Measurement of glucose absorption 
from the averted jejunal sac 
preparation  
 
Final Data Analysis 
in vitro -glucosidase 
inhibition assay 
in vitro -amylase inhibition 
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in vivo enzyme 
inhibition assay 
Histological 
assesment 
Data analysis 
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1.4. Objectives of the study 
The present study was conducted with the following objectives: 
1. To evaluate the hypoglycaemic and glucose tolerance effects of Syzygium 
polyanthum (Wight) leaf    
2. To evaluate the anti-hyperglycaemic action of Syzygium polyanthum (Wight) 
leaf on streptozotocin-induced diabetic rats and determine the most active 
extract, fraction and subfraction of Syzygium polyanthum leaf.  
3. To illucidate the phytochemistry of the most active extract, fraction and 
subfraction of Syzygium polyanthum (Wight) leaf. 
4. To evaluate the anti-hyperglycaemic activity of the active compound in 
Syzygium polyanthum (Wight) leaf. 
5. To examine the possible mechanisms of action of Syzygium polyanthum 
(Wight) leaf as an anti-diabetic agent. 
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CHAPTER TWO 
HYPOGLYCAEMIC, GLUCOSE TOLERANCE, AND ANTI-
HYPERGLYCAEMIC PROPERTIES OF SYZYGIUM POLYANTHUM 
(WIGHT) LEAF 
 
 
2.1.Introduction 
The anti-diabetic activities of plants can be assessed clinically in humans, either in 
vivo, using animal models, or in vitro, using a variety of test systems (Soumyanath, 
2005). Preliminary testing of herbs in animal models has historically played a critical 
role in the exploration and characterization of disease pathophysiology, target 
identification, and in vivo evaluation of novel therapeutic agents and treatments 
(McGonigle & Ruggeri, 2014; Soumyanath, 2006). Since results in in vitro studies 
need to be supported and verified by in vivo findings, proper models must be chosen 
(Kasmuri, 2006). Several methods for studying oral anti-hyperglycaemic activities in 
humans include clinical trials involving both normal and type 2 diabetic volunteers. 
In animals, evaluation of a chemical‟s effects on glucose levels has been conducted 
in normal animals (including rabbits, rats, mice and dogs), glucose-induced 
hyperglycaemic animals, and also in alloxan- and streptozotocin-induced diabetic 
animals (Evans, 2009). In the present study, two test approaches were employed, the 
hypoglycaemic and the intra-peritoneal glucose tolerance tests in normal rats.  
 
S. polyanthum is widely used in the Indonesian and the Malaysian cuisines, and it is 
also commonly used as a traditional medicine to treat diabetic patient in Indonesia 
(Agoes, 2010; Widyawati et al., 2012). The anti-hyperglycaemic activities of S. 
polyanthum extracts in different preparations and animal models have been reported 
(Anggadiredja, 1998; Studiawan & Santosa, 2005; Wahyono & Susanti, 2008), 
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however, none of the reported studies used sequential sample preparation or a 
bioactivity-guided approach. 
 
Sample preparation is the most important step in the development of analytical 
methods for the analysis of constituents present in herbal preparations (Ong, 2004). 
Research on medicinal plants should be conducted beyond biological activity 
screening and should be tailored towards systematic standardization and must 
following the quality assessment and evaluation guidelines (Ali et al., 2012; Bauer & 
Tittle, 1996; Ong, 2004; World Health Organisation WHO, 2000). The polarity of 
the solvent, the method of extraction, and the stability of the constituents may also 
influence the composition and quality of the extracts, and they must, therefore, be 
kept constant (Bauer, 1998; Handa et al., 2008). Preparation methods are tailored to 
the type of the natural material that is being processed, and the chosen strategy of 
analysis (Evans, 2009). In the present study, the dry powdered leaves were extracted 
sequentially using different solvents of varying polarities, starting with the non-polar 
and proceeding step by step using more polar solvents to obtain the crude extracts, 
fractions and subfractions. The activity of each extract obtained after each step of 
extraction was investigated to determine the most active  extract, fraction and 
subfraction. 
 
Basically, there are two main mechanisms for oral anti-diabetic action: which are 
insulin secretion induction and insulin sensitization (Brunton & Parker, 2006; Golan, 
2005; Katzung, 2004; Shu & Myers, 2004). These actions result in different effects, 
known as hypoglycaemic and anti-hyperglycaemic.  
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A hypoglycemic agent, like glibenclamide, could lower high blood glucose levels to 
be below the normal fasting level (below 3.8 mg/dL), while an anti-hyperglycaemic 
agent, like metformin, albeit also being able to lower high blood glucose levels, 
generally cannot bring them below the normal fasting level (4-6 mmol/L) (Brunton 
& Parker, 2006; Nolte & Karam, 2004; Yakubovich & Gerstein, 2011).  
 
The diabetic condition can either occur spontaneously, or be induced by chemicals,  
diets or surgical manipulations, and/or by a combination of these (Fröde & Medeiros, 
2008; Srinivasan & Ramarao, 2012). Experimental induction of diabetes mellitus in 
animal models is essential for the advancement of our knowledge and understanding 
of the various aspects of its pathogenesis, and for, ultimately, finding new therapies 
and cures (Suresh et al., 2012). Streptozotocin (STZ) is often and routinely used to 
induce diabetes in several species, including rats. This chemical can cause fatal 
transitional hypoglycaemia, which typically occurs 4-8 h after injection and lasts for 
several hours, due to the massive -cell islet necrosis and cell membrane rupture that  
produces a flood of insulin in the circulation (Srinivasan & Ramarao, 2012). The 
present study used STZ, which exerts its diabetogenic action when administered 
parenterally (i.e. intra-peritoneally). Experimental protocols recommend that 
administration of STZ be done in a fasting period (8-12 h), and be followed by the 
administration of a glucose solution (10%) to avoid hypoglycaemia, a condition in 
which blood glucose level fall below the lower normal level (below 3.8 mmol/L),  
for 24 hours as described above (Fröde & Medeiros, 2008; Wu & Huan, 2008).  
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Furthermore, the present study used male rats because male pancreatic -cells islets 
are more prone to STZ-induced cytotoxicity in comparison with those of the female 
rats of the same species (Wu & Huan, 2008). 
 
Even the most promising of novel pharmacological therapies would fail in clinical 
trials if it was unable to reach the target organ at a sufficient concentration to give the 
therapeutic effect. When dealing with animals or human subjects, the exact 
concentration of the drug at the receptor is unknown. However, the concentration is 
correlated to the administered dose as higher doses indicate greater concentrations at 
the receptor. Thus, all drugs must meet certain minimal requirements to achieve their 
clinical effectiveness (Pandit, 2007; Shu & Myers, 2004).  
 
The pharmacodynamics of a drug can be quantified by examining the relationship  
between the dose or the concentration of the drug and the organism‟s response to that 
drug. Increased concentrations of a drug increase the magnitude of its pharmacologi-                          
cal effect. A useful assumption is that response to a drug is proportional to the con- 
centration of the receptors that are bound or occupied by the drug (Harvey, 2012; 
Shu & Myers, 2004). This study used different doses of the extracts to find the  
correlation between these doses and the responses, and to confirm that the previously 
observed pharmacological effect was genuine and not coincidental. 
 
About 40% of prescriptions drugs are derived from herbs (Shanmuga, 2014) and 
many conventional drugs have been derived from prototypic molecules in medicinal 
plants, like the anti-diabetic biguanide class agent, metformin. This compound was 
obtained from a medicinal plant named Galega officinalis (Dey, Attele, & Yuan, 
